# Venlafaxine and vortioxetine co-administration (the 2V combination) in the treatment of patients with major depressive disorder: a case series exploring broader mechanisms for broader symptom targeting - URL: https://alisanburak.com/en/wcp-2026-posterler/ev0327 - Language: en - Last updated: not specified - Page title: Venlafaxine and vortioxetine co-administration (the 2V combination) in the treatment of patients with major depressive disorder: a case series exploring broader mechanisms for broader symptom targeting | WCP 2026 Summary > A higher level of functional recovery was observed following the addition of a second antidepressant in patients with MDD who had not achieved full recovery wi… This page was translated automatically from Turkish. [Read the original](https://alisanburak.com/wcp-2026-posterler/ev0327) This page is an AI-assisted Turkish summary of the study presented at the 26th World Congress of Psychiatry. The study belongs to the presenting authors; please refer to the original source when citing it. EV0327 E-PosterPsychopharmacologyCase series # Venlafaxine and vortioxetine co-administration (the 2V combination) in the treatment of patients with major depressive disorder: a case series exploring broader mechanisms for broader symptom targeting COMBINING VENLAFAXINE AND VORTIOXETINE (2VS COMBINATION) IN TREATING PATIENTS WITH MDD CASE SERIES: BROADER MECHANISM FOR BROADER SYMPTOMS’ TARGETING Presenter: Mohammed A. Allam Country: United Arab Emirates A higher level of functional recovery was observed following the addition of a second antidepressant in patients with MDD who had not achieved full recovery with monotherapy. The aim is to present a case series involving the use of vortioxetine and venlafaxine together (the 2V combination) in patients with major depressive disorder (MDD). The rationale is that two distinct, complementary mechanisms of action may target a broader range of symptoms in patients with heterogeneous etiologies and individual genetic predispositions. In the methods, a second medication was added for patients who had received well-tolerated monotherapy with one of the two medications for an adequate duration but had not achieved full symptomatic and functional recovery; neither antidepressant was used as an initial treatment. Follow-up notes documented patients’ baseline symptom profiles, their course at follow-up visits, and their status after the addition of the second medication. Functional recovery was assessed from the patients’ own perspectives, based on their functioning at work and what they were able to do compared with the period when they had been at their best. The findings indicated a higher level of functional recovery after the addition of the second antidepressant. Across the eight cases, the lowest doses used were 150 mg for venlafaxine and 20 mg for vortioxetine. The author identifies the exclusion of patients who responded poorly to the same combination as a statistical limitation and emphasizes the need for larger-scale naturalistic observational studies focusing on measuring functional recovery and identifying which symptoms are likely to benefit. [View the original poster](https://cslide.ctimeetingtech.com/wcp26/attendee/eposter/file/39) How to cite this study APA 7: Allam, M. A. (2026, September 23-26). Combining venlafaxine and vortioxetine (2vs combination) in treating patients with mdd case series: broader mechanism for broader symptoms’ targeting [E-poster]. 26th WPA World Congress of Psychiatry (WCP 2026), Stockholm, Sweden. https://cslide.ctimeetingtech.com/wcp26/attendee/eposter/file/39 Vancouver: Allam MA. Combining venlafaxine and vortioxetine (2vs combination) in treating patients with mdd case series: broader mechanism for broader symptoms’ targeting [e-poster]. 26th WPA World Congress of Psychiatry (WCP 2026); 2026 Sep 23-26; Stockholm, Sweden. Available from: https://cslide.ctimeetingtech.com/wcp26/attendee/eposter/file/39 Author names and title formatting were generated automatically from the congress system; please check them against the original poster before use. ## On the same topic - [Açığı kapatmak: erişkin DEHB ilacı başlanmadan önce EKG sevk uyumunun iyileştirilmesi, kapalı döngü klinik denetim](https://alisanburak.com/en/wcp-2026-posterler/ev0088) - [Anksiyete bozukluğu olan hastalarda psikobiyotik müdahalesi: ısıl işlem görmüş Lactobacillus paracasei PS23'ün etkilerini inceleyen çift kör randomize kontrollü çalışma](https://alisanburak.com/en/wcp-2026-posterler/ev0126) - [Otizm spektrum bozukluğunda bumetanidin tedavi edici potansiyeli: güncel kanıtlar ve gelecek yönelimleri](https://alisanburak.com/en/wcp-2026-posterler/ev0157) - [Verbaskozid ile otizm spektrum bozukluğu tedavisinin mekanizmaları: ağ farmakolojisi, moleküler yerleştirme ve moleküler dinamik temelli inceleme](https://alisanburak.com/en/wcp-2026-posterler/ev0172) - [Otizm spektrum bozukluğunun çekirdek belirtilerinin tedavisinde kannabidiol: sistematik derleme](https://alisanburak.com/en/wcp-2026-posterler/ev0186) [All WCP 2026 summaries](https://alisanburak.com/en/wcp-2026-posterler) --- Kaynak / Source: https://alisanburak.com/en/wcp-2026-posterler/ev0327 İletişim / Contact: Bağdat Caddesi, Veli Güneysu Apt. No:453 K:4 D:9, Suadiye / Kadıköy, İstanbul · +90 532 642 95 25 · info@alisanburak.com · https://alisanburak.com/bagdat-caddesi-psikoterapi-iletisim